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Ultrasound contrast agents are known to enhance high intensity focused ultrasound (HIFU) ablation,
but these perfluorocarbon microbubbles are limited to the vasculature, have a short half-life in vivo,
and may result in unintended heating away from the target site. Herein, a nano-sized (100–300 nm),
dual perfluorocarbon (decafluorobutane/dodecafluoropentane) droplet that is stable, is sufficiently
small to extravasate, and is convertible to micron-sized bubbles upon acoustic activation was investi-
gated. Microbubbles and nanodroplets were incorporated into tissue-mimicking acrylamide-albumin
phantoms. Microbubbles or nanodroplets at 0.1 106 per cm3 resulted in mean lesion volumes of
80.4 6 33.1 mm3 and 52.8 6 14.2 mm3 (mean 6 s.e.), respectively, after 20 s of continuous 1 MHz
HIFU at a peak negative pressure of 4 MPa, compared to a lesion volume of 1.0 6 0.8 mm3 in agent-
free control phantoms. Magnetic resonance thermometry mapping during HIFU confirmed undesired
surface heating in phantoms containing microbubbles, whereas heating occurred at the acoustic focus
of phantoms containing the nanodroplets. Maximal change in temperature at the target site was
enhanced by 16.9% and 37.0% by microbubbles and nanodroplets, respectively. This perfluorocarbon
nanodroplet has the potential to reduce the time to ablate tumors by one-third during focused ultra-
sound surgery while also safely enhancing thermal deposition at the target site.
VC 2013 Acoustical Society of America. [http://dx.doi.org/10.1121/1.4812866]
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I. INTRODUCTION
High intensity focused ultrasound (HIFU) is a non-
invasive thermal ablation technique for the treatment of be-
nign and malignant solid masses. In some countries, HIFU is
approved to treat prostate cancer, and in the U.S., HIFU is
approved by the Food and Drug Administration for the treat-
ment of uterine fibroids (Ringold, 2004; Gedroyc and
Anstee, 2007; Lukka et al., 2011). HIFU is also under pre-
clinical investigation as a potential treatment option for tu-
mor malignancies located in brain, liver, prostate, pancreas,
bone, and breast (Hill and terHaar, 1995; Kennedy, 2005;
Pauly et al., 2006; Wu et al., 2007; Kinsey et al., 2008;
Maleke and Konofagou, 2008; Liberman et al., 2009;
Fischer et al., 2010; Jang et al., 2010; Maleke and
Konofagou, 2010; McDannold et al., 2010; Tempany et al.,
2011). Because HIFU requires no invasive procedures, radia-
tion, or chemotherapy, it offers advantages over standard
cancer therapy. Nevertheless, there are limitations to HIFU.
A single ellipsoid volume (15–25 mm3) is exposed to acous-
tic pulses with intensities above 10 000 W/cm2. This power
requirement carries a risk of uncontrolled tissue cavitation
(Coussios et al., 2007; Kyriakou et al., 2011), and therefore
exposure times are brief and separated by a period of heat
dissipation. Hundreds of lesions and hours of therapy are of-
ten needed to treat a single tumor. Additionally, healthy tis-
sue in the path of the high-energy acoustic beam is at risk for
thermal injury (Mougenot et al., 2011). Unintended heating
can also occur near structures that attenuate or reflect ultra-
sound (air cavities or bone) (Connor and Hynynen, 2004;
McDannold et al., 2004). In response to these limitations,
methods to lower the acoustic power requirements and treat-
ment times to achieve ablation with HIFU are currently
under investigation.
Research over the past decade has demonstrated that the
presence of ultrasound contrast agents, or microbubbles, in a
HIFU field substantially decreases the acoustic energy
required to ablate tissue (Tran et al., 2003; Liu et al., 2006;
Tung et al., 2006; Yu et al., 2006a; Yu et al., 2006b; Stride
and Coussios, 2010). Microbubbles are FDA-approved ultra-
sound contrast agents that are micron-sized gas (typically
perfluorocarbon) bubbles with a polymer, protein, or lipid
shell (Goldberg et al., 1994). Insonated microbubbles reso-
nate, generating additional heat, and collapse (cavitation),
producing local shock waves that cause mechanical stress at
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the cellular level (Tran et al., 2003; Xu et al., 2005) thereby
aiding tissue ablation. However, the clinical translation of
microbubbles as an ablation mediator in treating tumors is
fundamentally limited because microbubbles are (1) too
large to extravasate from the vascular space (Ferrara et al.,
2007; Villanueva, 2008) and (2) have a very short half-life
in vivo (minutes) (Mullin et al., 2011). The production of
stable microbubbles smaller than a micron is particularly
challenging (Ganan-Calvo, 2004; Talu et al., 2006; Xu et al.,
2006), and furthermore microbubbles much less than a
micron respond poorly to low frequency ultrasound (Dayton
et al., 1999; Chomas et al., 2001a; Chomas et al., 2001b).
Thus an alternative to traditional microbubbles is needed for
focused ultrasound-mediated tumor applications.
An alternative to microbubbles is liquid perfluorocarbon
(PFC)-based agents. Liquid PFC droplets can have a sub-
stantially longer circulation half-life than gas-filled micro-
bubbles (Rapoport et al., 2011). Furthermore, under
sufficient acoustic energy, certain PFCs can be phase-shifted
from liquid to gas form, resulting in microbubbles at the tar-
get site. Indeed, phase-change PFCs have been proposed as
mediators for HIFU thermal delivery for this reason (Zhang
and Porter, 2010; Zhang et al., 2011).
Micron-sized liquid-based PFC agents have been stud-
ied extensively in ultrasound applications as agents for vas-
cular occlusion (Kripfgans et al., 2002; Kripfgans et al.,
2005). However, micron-sized PFC agents cannot access the
extravascular space due to their size and thus would not
accumulate in tumors. Hence the application of micron-sized
PFC droplets in focused ultrasound surgery for tumor treat-
ment is limited.
In response to the limitations inherent in the use of
microbubbles and micron-sized droplets, efforts are now
focused on nano-sized agents with the development of sev-
eral techniques to synthesize stable liquid PFC nanodroplets
(Kawabata et al., 2010; Rapoport et al., 2010; Zhang and
Porter, 2010; Reznik et al., 2011; Sheeran et al., 2011a;
Sheeran et al., 2012; Singh et al., 2012). When designed
appropriately, PFC nanodroplets can be phase-shifted to gas-
eous microbubbles by the application of sufficient acoustic
energy (Sheeran and Dayton, 2012). The acoustic parameters
(HIFU intensity) required to initiate vaporization of the PFC
droplet depend on the size of the droplet and its chemical
composition (Rapoport et al., 2009; Sheeran et al., 2011b;
Singh et al., 2012). Taking advantage of temperature-
pressure requirements for nanodroplet vaporization, our
laboratory has synthesized unique phase-shift liquid nano-
droplets using highly volatile PFCs, including decafluorobu-
tane (DFB, C4F10, b.p.¼2 C). Because these novel
nanodroplets vaporize at a controlled pressure, they are
expected to enhance thermal energy deposition only at the
acoustic focus where the pressure is sufficiently high to
vaporize nanodroplets into microbubbles.
We hypothesized that our new nanodroplet PFC formu-
lation would thermally and spatially enhance HIFU ablation
at the intended target site. Furthermore we predicted that
these nanodroplets would provide more control over lesion
size and placement than microbubbles and also enable short-
ening of heating times and/or lessening of delivered acoustic
energy. We examined the thermal enhancement of the hybrid
nanodroplets relative to standard microbubble formulations
and agent free controls in a tissue mimicking acrylamide-
albumin phantom in response to HIFU. Specifically, we
assessed the relationship among agent concentration, acous-
tic pressure, and pulse length on vaporization threshold,
lesion size, lesion location, and thermal enhancement.
Finally, we examined temperature profiles during HIFU
ablation by magnetic resonance (MR) thermometry.
II. MATERIALS AND METHODS
A. Microbubble preparation and condensation to
nanodroplets
The phase-shift nanodroplets used in this study and their
precursor microbubbles have PFC cores containing a mixture
of DFB (C4F10) and dodecafluoropentane (DDFP, C5F12)
encapsulated in a phospholipid shell. Lipids were purchased
from Avanti Polar Lipids (Alabaster, AL), and PFCs were
purchased from Fluoromed (Round Rock, TX). Lipid emul-
sions were formulated by dissolving 1,2-distearoyl-sn-
glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy(polyethylene-glycol)-2000
in a 9:1 M ratio and a total lipid concentration of 1.0 mg/ml
in a solution of phosphate-buffered saline (PBS), propylene
glycol, and glycerol as previously described (Sheeran et al.,
2012). A total of 1.5 ml lipid mixture was added to a 3 ml
glass vial, and the headspace of the vial was then gas-
exchanged with a 1:1 mixture of DFB:DDFP gas. All micro-
bubbles with a PFC core and a phospholipid shell arranged
spontaneously during agitation using a Vialmix Shaker
(Bristol-Myers-Squibb, NY, NY). Microbubble stock solu-
tions contain approximately 1010 microbubbles/ml.
Nanodroplets were formed by the condensation of the
precursor microbubbles as previously described (Sheeran
et al., 2011a). Briefly, the 3 ml vials containing microbub-
bles were immersed in a CO2/isopropanol bath controlled to
a temperature between 5 C and 10 C and swirled gently
for approximately 1 min. The vials were connected to an ad-
justable air pressure source, and headspace pressure in the
vial was increased until a change in the consistency was
noted in the microbubble solution, indicating the onset of
condensation. The combination of propylene glycol, glyc-
erol, and PBS prevents freezing during the approximately
2 min exposure to sub-zero temperature. After condensation,
the pressure source was removed from the vial, leaving a
pressure head on the solution until further use. Assuming a
direct conversion between the gas and liquid states, nano-
droplet stock solutions also contain approximately 1010
nanodroplets/ml.
B. Nanodroplet and microbubble sizing
Microbubble concentration and size distributions were
measured in triplicate using an Accusizer 780 (Particle
Sizing Systems, Santa Barbara, CA) with a lower detection
limit of 0.5 lm. Dynamic light scattering (Malvern Nano ZS,
Malvern Instruments, Westborough, MA) with a measure-
ment range of 0.3 nm to 6 lm diameters was used to assess
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size distributions of the nanodroplets. The condensed nano-
droplet solution was transferred to a cuvette immediately
prior to sizing. Stability of the nanodroplets in stock solution
was assessed by repeated sizing several hours/days after their
condensation at 37 C as performed previously (Sheeran
et al., 2012).
C. Tissue-mimicking phantoms
Acrylamide-albumin tissue mimicking phantom, similar
to those previously described (Takegami et al., 2004), were
created from an 8:7:5 mixture of an aqueous acrylamide so-
lution, liquid egg white, and deionized water, respectively.
The advantage of these phantoms is their near transparency
until heated above 60 C. Upon reaching this ablation thresh-
old, the egg whites are permanently denatured, creating a
visibly opaque lesion. Controlled volumes (0.0025–1 ll/ml
of phantom material) of the stock microbubble or nanodrop-
let solutions were added to the phantom acrylamide solution
to generate various agent concentrations within the phan-
toms. Agents were gently dispersed throughout the degassed
acrylamide solution prior to polymerization via the addition
of 1% vol./vol. of 10% ammonium persulfate and 0.4%
vol./vol. tetramethylethylenediamine, and then the solution
was poured into an angled cylindrical mold. The top and
bottom diameters of the phantoms were 3 and 4.1 cm,
respectively, with a height of 1.5 cm, resulting in a total vol-
ume of 10 ml. Because the stock solutions of nanodroplets
and microbubbles contained approximately 1010 agents/ml,
the final concentrations of nanodroplets and microbubbles in
the tissue-mimicking phantoms ranged from 104 to 107
agents/ml. For comparison, the prescribing information for
Definity
VR
suggests injecting 1.2 108 microbubbles/kg
(or roughly 1.2 105 microbubbles/g), and we incorporate
roughly the same number per gram of phantom tissue
when 0.01 ll of stock agent solution is added per milliliter of
phantom material. From this point on, the nanodroplet or
microbubble concentration will be referenced by the microli-
ters (ll) of stock solution added per milliliter of phantom
material. All phantoms were used within 48 h of their
generation.
D. Tumor-mimicking model for HIFU ablation
To simulate a tumor surrounded by healthy tissue, the
10 ml phantom (mimicking the tumor mass) was placed
within an agent-free gellan gum mold and separated from
the ultrasound transducer by a 10 mm thick degassed, agent-
free acrylamide-albumin gel cap (Fig. 1). This mold and cap
(mimicking healthy tissue surrounding the tumor) were posi-
tioned below the HIFU transducer such that the center of the
phantom was at the focal point of the HIFU beam. The
agent-free gels encasing the phantom allowed for assessment
of thermal damage outside of the intended ablation area. The
tissue mimicking gels and mold were placed in a bath of cir-
culating degassed water to maintain a constant temperature
of 37 C. An acoustic absorbent pad was placed below the
bottom mold to minimize possible sound wave reflection off
the acrylic floor of the water bath.
E. Focused ultrasound
HIFU was delivered by a spherically focused, eight-
element, 1.2 MHz, transducer array (Imasonic, Voray-sur-
l’Ognon, France) driven by a therapy imaging probe system
(TIPS) (Philips Research North America, Briarcliff Manor,
NY). The diameter and focal length of the transducer were
both 80 mm. Continuous-wave HIFU was applied at 1 MHz
in all studies and delivered at peak negative pressures
(PNPs) of 1, 2, 3, and 4 MPa. Calibration at each pressure
was determined using a needle hydrophone (Onda HNA-
0400, Sunnyvale, CA) in a degassed water bath. The applied
acoustic intensities are approximately 30 W/cm2 at 1 MPa,
125 W/cm2 at 2 MPa, 280 W/cm2 at 3 MPa, and 500 W/cm2
at 4 MPa. Precise axial and lateral positioning of the focal
point (TIPS focal zone: 1 1 6 mm) was achieved by
using a three-dimensional (3-D) motion stage.
F. Acoustic imaging of the onset of vaporization and
the volume of the vaporization field
Liquid nanodroplets at the low concentrations used in
this study are not acoustically detectable by conventional
ultrasound imaging prior to vaporization. Therefore both
control phantoms and those containing nanodroplets are
acoustically transparent. To date, nanodroplet vaporization
has most often been assessed in small capillary tubes con-
taining aqueous solutions by the passive detection of emitted
acoustic signatures. In this study, nanodroplet vaporization
was assessed directly in the tissue-mimicking gel by acoustic
imaging of the echogenic microbubble cloud (vaporization
field) that forms during the application of HIFU. In order to
determine the onset of vaporization, acoustic imaging was
performed after the application of continuous-wave HIFU at
pressures of 1, 2, 3, and 4 MPa to phantoms containing 0.1 ll
of nanodroplet stock per ml for exposure times ranging from
2 ms to 20 s.
Each phantom was sonicated only once and then imme-
diately imaged using a 15L8 transducer probe with a
FIG. 1. (Color online) (Left) A tissue-mimicking albumin-acrylamide phan-
tom (AAP) containing nanodroplets was positioned between a tissue-
mimicking gellan gum base below and an agent free albumin-acrylamide
cap above. High intensity focused ultrasound (HIFU) was directed toward
the center of the phantom from above. The image on the right is a represen-
tative pre-HIFU acoustic image of the aligned phantoms with a nanodroplet
phantom in the center. The white ellipse denotes the location and approxi-
mate dimensions of the acoustic focus where ablation was performed.
Notice that no agents are visible within the phantom prior to HIFU.
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Siemens Sequoia scanner (Siemens, Mountain View, CA)
operating in B-mode at 14 MHz. Testing was performed in
triplicate. Dicom images were analyzed offline by IMAGEJ
software (http://rsbweb.nih.gov/ij/). An ellipse region of in-
terest (ROI) measuring the size of the known focal beam
dimensions was drawn within each image at the site of va-
porization. A second equally sized ellipse was drawn on the
unaffected region of the phantom, at least 5 mm to the left or
right, but within the same image, as a measure of back-
ground intensity. Pixel intensity in each ellipse was meas-
ured and the mean calculated. The background mean was
subtracted from the mean pixel intensity in the vaporization
ROI, and the pixel intensity was plotted against time to
determine the onset of vaporization.
In a separate set of experiments, the final volume of the
vaporization field (microbubble cloud) was determined in
phantoms containing 0.05, 0.1, 0.25, or 1.0 ll of nanodroplet
stock per milliliter that were insonated by continuous-wave
HIFU for 20 s at 1, 2, 3, and 4 MPa. The phantoms were
imaged immediately after HIFU application using the 15L8
transducer probe and Siemens Sequoia scanner operating in
B-mode at 14 MHz (Fig. 1). The width and height of the va-
porization field were measured, and the corresponding va-
porization field volume was estimated as an ellipsoid and
calculated as described in the following section.
G. Lesion formation as a function of concentration of
agents and of pressure
Acrylamide-albumin phantoms containing between
0.0025 and 1 ll of stock nanodroplet or microbubble solution
per milliliter of phantom material were insonated by continu-
ous wave HIFU for 20 s at 1 MHz using PNPs of 1, 2, 3, or
4 MPa. All experiments were repeated in at least triplicate.
Ablation lesions were visible as opaque regions in the other-
wise transparent phantom. Phantoms were cut by scalpel,
and the maximum height (vertical axis) and width (lateral
axis) of each ablation lesion was determined by direct visual-
ization and measured by calipers. The volume of the ellip-
soid lesion was calculated using the formula
volume ¼ ð4=3Þ  p  ðmaximum height=2Þ
 ðmaximum width=2Þ2: (1)
H. MR thermometry
MR thermometry was applied to investigate thermal
deposition in phantoms containing nanodroplets and micro-
bubbles. MR imaging was performed at 3T (Magnetom Trio,
Siemens Healthcare, Malvern, PA) using a custom 2-in.
square, single-loop, receive-only RF coil (FUS Instruments,
Toronto, Canada). Ultrasound sonication was performed
inside the scanner using an MR-compatible system consist-
ing of a focused 1 MHz transducer (75 mm diameter,
F#¼ 0.8) with three-axis motor control (RKO-100, FUS
Instruments). Albumin-acrylamide gel phantoms containing
no agent (control), nanodroplets (0.005 ll/ml, 0.01 ll/ml, or
0.1 ll/ml), or microbubbles (0.005 ll/ml or 0.01 ll/ml) were
insonated by continuous wave HIFU at 1.1 MHz with a PNP
of 4.69 MPa (20 W) for 60 s. For each application of HIFU,
the temperature was monitored either in a single vertical
slice or in three parallel horizontal (perpendicular to the axis
of the acoustic beam) slices (see Fig. 2). The center-to-center
slice spacing was 4.5 mm for the horizontal scans.
All MR images were acquired using a 2D multi-slice,
spoiled gradient-echo pulse sequence with the following pa-
rameters: TR/TE¼ 39/5 ms, field of view¼ 51 102 mm,
matrix¼ 64 128, in-plane resolution¼ 0.8 0.8 mm, read-
out bandwidth¼ 220 Hz/pixel, flip angle¼ 25, slice thick-
ness¼ 2.5 mm, scan time¼ 2.5 s per image set. For each
ultrasound application, 50 consecutive image sets were
acquired back to back for a total scan time of 2 min and 5 s.
Ultrasound sonication was initiated 5 s into the MR scan (im-
mediately following acquisition of the second image set),
lasted for 60 s, and imaging continued for an additional 60 s
during cool-down.
Maps of the temperature evolution during and post each
ultrasound application were computed from the MR images
using the proton resonance frequency shift method
(Hindman, 1966; Ishihara et al., 1995), similar to previously
described thermometry studies (Germain et al., 2001; Rieke
and Pauly, 2008). Specifically, the temperature change dur-
ing the scan was computed from the phase difference
between the second image (acquired immediately before
starting the sonication) and each subsequent image of the
scan, assuming 0.01 ppm/ C temperature sensitivity at the
actual scanner field strength of 2.89 T.
I. Statistical analysis
Data sets were evaluated using Student’s t-tests in the
case of paired means and were evaluated by one-way analy-
sis of variance (ANOVA) when more than two groups were
compared. All results are reported as the mean of that data
FIG. 2. Schematic representation of the AAP position above the HIFU trans-
ducer. The acoustic focus was positioned directly in the center of the phan-
tom. Horizontal MR slices were collected at the focus, at the surface of the
phantom, and in between these two slices. During separate scans, vertical
slices were collected parallel to the axial length of the acoustic focus.
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and its corresponding standard deviation. In cases where n
was not equal across data sets, standard error is reported. All
experiments were performed in at least triplicate, and p val-
ues of <0.05 were considered to be statistically significant.
III. RESULTS
A. Nanodroplet and microbubble size
The average diameter of the nanodroplet population was
measured to be 240 6 65 nm by dynamic light scattering.
Nanodroplets remained stable in solution at 37 C for at least
48 h after condensation. As assessed by laser light diffrac-
tion, the mean microbubble diameter was 0.98 6 0.68 lm.
B. Onset of vaporization
In phantoms containing 0.1 ll of stock nanodroplets, va-
porization of the nanodroplets at the HIFU focus generated a
central bubble cloud. Acoustic B-mode imaging confirmed
vaporization in the focal region within 10–20 ms of HIFU
exposure at 2, 3, and 4 MPa [Fig. 3(A)]. No significant va-
porization was observed prior to 10 ms of HIFU exposure at
any pressure. No vaporization could be detected when HIFU
was applied at a pressure of 1 MPa (corresponding to an in-
tensity of 30 W/cm2) regardless of the nanodroplet concen-
tration. The mean pixel intensity within the acoustic focal
area was measured as a function of pulse length [Fig. 3(B)].
Nanodroplets within the path of the beam but outside the
focal spot did not experience sufficient pressure or heating to
vaporize. HIFU delivered at 4 MPa resulted in a vaporization
field (microbubble cloud) that was significantly larger than
the corresponding ablation lesion that was formed within it
(400 vs 150 mm3).
C. Vaporization field volume
Vaporization field volumes were measured as a function
of nanodroplet concentration and acoustic pressure [Fig.
3(C)]. The vaporization field volume increased both with
increasing nanodroplet concentration and with the applica-
tion of higher acoustic pressures. Applying continuous wave
HIFU at 1 MHz for 20 s with a PNP of 4 MPa to a phantom
containing 1 ll of the stock nanodroplet solution per millili-
ter produced a vaporization field volume of approximately
400 mm3. At 2 MPa, the vaporization field volume was
approximately 100 mm3 [Fig. 3(C)]. No vaporization field
could be detected in control phantoms (containing no nano-
droplets) below 4 MPa.
D. Ablation lesion volume
Ablation lesion volumes were measured as a function of
nanodroplet and microbubble concentration and acoustic
pressure (Fig. 4). HIFU at 1 MPa for 20 s did not result in
ablation lesion formation at any tested nanodroplet or micro-
bubble concentration. At least 2 MPa of pressure was
required to induce ablation. The volumes of the ablation
lesions were highly dependent on the concentration of nano-
droplets and microbubbles in the tissue-mimicking phantom
and also on the PNP of insonation. For each acoustic
pressure applied, ablation lesion volumes increased over sev-
eral orders of magnitude of increasing nanodroplet (0–1 ll/
ml) and microbubble (0–0.1 ll/ml) concentrations (Fig. 5).
However, there were significant differences between the vol-
umes of ablation lesions produced in phantoms containing
nanodroplets compared to microbubbles. For each pressure,
FIG. 3. Vaporization of nanodroplets in tissue-mimicking phantoms. (A)
Representative acoustic image of vaporized nanodroplets in a phantom con-
taining 0.1 ll of stock solution per milliliter. Notice no vaporization is pres-
ent outside the focal zone or in the cap. An ellipse region of interest (ROI)
measuring 1.5 mm 10 mm was measured at the site of vaporization. (B)
Mean pixel intensity within the ROI was assessed in phantoms containing
0.1 ll of nanodroplet stock per milliliter as a function of pulse length (n 3,
mean 6 s.d.). (C) Vaporization volume resulting from 20 s of HIFU as a
function of nanodroplet concentration over a range of pressure from 2-
4 MPa (n 3, mean 6 s.d.).
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the presence of microbubbles resulted in larger lesions than
nanodroplets. At 4 MPa, ablation lesions achieved a peak av-
erage volume of approximately 300 mm3 in phantoms con-
taining microbubbles compared to a maximum volume
approaching 150 mm3 with nanodroplets. Maximum ablation
lesion volume was achieved with microbubbles at a concen-
tration that was a full order of magnitude lower than the
required nanodroplet concentration (0.1 vs 1 ll/ml) to reach
the same ablation volume. Even at low concentrations, both
agents enhanced lesion volume. Microbubbles or nanodrop-
lets at the 0.01 ll/ml concentration (0.1 106 per cm3)
resulted in mean lesion volumes of 80.4 6 33.1 and
52.8 6 14.2 mm3 (mean 6 s.e.), respectively, after 20 s of
continuous 1 MHz HIFU at a PNP of 4 MPa (Fig. 5). In com-
parison, lesion volumes of 1.0 6 0.8 mm3 were generated in
agent-free control phantoms under the same HIFU parame-
ters. Lesion volume continually increased with increasing
nanodroplet concentration over the entire range investigated.
However, this was not true in phantoms containing micro-
bubbles. The lesion volume decreased in phantoms contain-
ing more than 0.1 ll of microbubble stock per ml [Fig. 5(C)].
Eventually at concentrations of microbubbles greater than
1 ll/ml, ablation lesions formed only at the surface of the
phantom and were too flat to accurately measure. As such,
no data on these concentrations are presented.
E. Ablation lesion geometry and location
Differences in the shape of the ablation lesions produced
by nanodroplet or microbubble-enhanced HIFU, as well as
differences in the location of these lesions within the phan-
tom, were analyzed by direct visualization and lesion mea-
surement. The ideal lesion is a prolate ellipsoid (vertical
axis> lateral axis) centered at the HIFU focal point.
However, with increasing microbubble concentrations, the
vertical axis of the ablation lesion shortens while the lateral
FIG. 4. Ablation lesion volume as a function of (A) nanodroplet (ND) or (B)
microbubble (MB) concentration. Lesion volumes resulted from 20 s of
HIFU at 2, 3, or 4 MPa (n 3, mean 6 s.d.).
FIG. 5. (Color online) Ablation lesion height (A), width (B), and corresponding volume (C) as a function of ND or MB concentration in tissue-mimicking
phantoms following HIFU exposure for 20 s at 4 MPa PNP. (D) Representative images of lesions formed inside the AAPs containing no agents, ND, or MB at
various concentrations. The location and size of each lesion is indicated by the superimposed white bracket. The white scale bar in the upper right corner of
each image represents 5 mm.
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axis widens [Figs. 5(A) and 5(B)]. The resultant lesions are
more oblate rather than prolate ellipsoids as microbubble
concentrations increase. This oblate geometry occurs in
phantoms with microbubble concentrations above 0.005 ll/
ml and occurs at the frontal surface of the phantom not
around the desired focal point at the center of the phantom
[Fig. 5(D)]. At a microbubble concentration of 0.1 ll/ml, the
largest ablation lesions were produced [Fig. 5(C)], but they
were spread out over the phantom surface [Fig. 5(D)]. In
contrast, lesions produced in nanodroplet phantoms retained
their desired prolate shape for a greater range of concentra-
tions [Fig. 5(D)]. These nanodroplet-associated prolate ellip-
soids remained localized around the central focal point [Fig.
5(D)].
F. MR thermometry
MR thermometry was performed during the insonation
of phantoms containing no (control) agents, 0.005 ll, or
0.01 ll of nanodroplets or microbubbles per milliliter by
continuous wave HIFU for 60 s at 1 MHz and a PNP of
4.69 MPa. MR data were collected every 2.5 s during and for
another 60 s following ablation. At each time point, the max-
imum intensity pixel along with its eight surrounding pixels
was averaged to obtain the localized maximum change in
temperature and is referred to as the “maximal temperature
change” from here on. The maximal temperature change
anywhere in the phantom over the 2 min data collection pe-
riod was determined from vertical MR slices [Fig. 6(A)].
The maximal changes in temperature at the acoustic focus
(ROI) and at the surface of the phantom were detected from
the horizontal MR slices acquired at each corresponding
plane [Figs. 6(B) and 6(C)].
Of all five types of non-control phantoms investigated,
HIFU ablation of the two containing 0.005 or 0.01 ll micro-
bubbles per milliliter and the phantom containing 0.1 ll of
nanodroplets per milliliter resulted in a significantly
enhanced temperature rise over the control (white bar in
graphs). However, it is important to note that the maximal
temperature rise did not occur at the same location within
each type of phantom (Fig. 7). The maximal temperature rise
occurred near the surface in microbubble phantoms, whereas
the phantoms that contained nanodroplets incurred a maxi-
mal temperature rise near the acoustic focus in the center of
the phantom. Maximal change in temperature at the acoustic
target site was enhanced by 16.9% and 37.0% by microbub-
bles and nanodroplets, respectively.
The temperature vs time curves (Fig. 8) acquired at the
surface of the phantoms and at the acoustic focus in the mid-
dle of the phantoms clearly illustrate the differences in ther-
mal energy deposition between the nanodroplet and
microbubble phantoms of the same 0.01 ll/ml concentration.
The temperature at the acoustic focus was highest in the
nanodroplet phantom and lowest in the control phantom.
The peak temperature in the control phantoms was observed
at the end of the HIFU application (60 s). The phantoms con-
taining 0.01 ll of nanodroplets per milliliter reached the
same temperature (15.4 C) after only 20 s, thereby decreas-
ing the ablation time needed. Minimal surface heating
occurred in the nanodroplet phantoms and was only higher
than the control after 40 s of ablation. The surface of the
microbubble phantoms rose by more than 50 but only rose
by about 19 at the targeted region of interest demonstrating
that the majority of the heating occurred away from the
intended target site.
IV. DISCUSSION
This study explored a novel phase-shift nanoagent for
enhanced HIFU ablation. These phase-shift nanodroplets
have a PFC core that combines highly volatile DFB with
less-volatile DDFP. The goal of combining PFCs was to bal-
ance stability and acoustic sensitivity. By combining DFB
and DDFP in a 1:1 mixture, vaporization and ablation was
achieved at relatively low HIFU intensities, yet droplets
were stable enough to remain intact in liquid form during
phantom preparation and storage. The results of these studies
demonstrated several advantages of these novel nanodroplets
FIG. 6. Temperature change in AAPs after 60 s of continuous HIFU ablation
at 20 W (4.69 MPa). The (A) maximal temperature change anywhere in the
vertical cross section of the phantom, the (B) change in temperature at the
location of the acoustic focus, and the (C) change in temperature at the sur-
face of the phantom are all listed for each type of phantom and concentra-
tion of agents in microliters (mean 6 s.e., *indicates p 0.05 compared to 0
agents, n 3).
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compared to gaseous PFC microbubbles—the clinical gold
standard for acoustic contrast imaging.
Vaporization of the PFC nanodroplets into microbubbles
was detected by acoustic imaging of the microbubble cloud.
The vaporization field volume results from the interdepend-
ent effects of the acoustic beam geometry and pressure (in-
tensity), temperature rise in the acoustic field, and the
concentration of nanodroplets. The vaporization volume
increased with increasing pulse length as was also reported
previously by others (Lo et al., 2007). However, at a sonica-
tion pressure of 4 MPa, large variability in the vaporization
field volumes occurred within the two highest nanodroplet
concentrations. This variability demonstrates the loss of con-
trol over lesion size, shape, and location that occurs in the
higher range of nanodroplet concentrations and acoustic
pressures. To induce an acoustically detectable vaporization
cloud from the nanodroplets, a pressure of at least 2 MPa
(PNP) for more than 10 ms was required. This threshold is
hypothesized to be one of the main reasons why unintended
heating within the prefocal zone was minimized in phantoms
containing nanodroplets. Indeed, prefocal surface heating in
nanodroplet phantoms was not significantly greater than sur-
face heating in control phantoms based on the MR thermom-
etry results.
HIFU ablation lesions in phantoms containing either
type of agent were statistically larger than control lesions,
but microbubbles were associated with surface heating and
loss of control over lesion placement with higher concentra-
tions. Previous studies have reported changes in lesion
geometry with increasing microbubble concentrations such
that ablation lesions become oblate ellipsoids (lateral
axis> vertical axis) massed at the frontal phantom surface
(Tung et al., 2006). In our study, continuous-wave HIFU
(20 s at 1 MHz and 4 MPa) produced ablation lesions with
volumes averaging approximately 300 mm3 in phantoms
containing microbubbles. Lesions of similar volume have
been reported in animal models of microbubble-enhanced
HIFU ablation. Kaneko et al. (2005) demonstrated ablation
lesions averaging almost 400 mm3 in rabbit liver in response
to 60 s of HIFU at an intensity of 400 W/cm2 using air-based
Levovist
VR
. However, these large lesions may not be desira-
ble. Tung et al. (2006) explored microbubble-enhanced
HIFU ablation using Definity, a gaseous perfluoropropane
contrast agent, in acrylamide-albumin gels. Although abla-
tion lesions were significantly larger in microbubble-
containing phantoms compared to control, undesirable
changes in ablation lesion shape and location occurred with
increasing microbubble concentrations. At lower microbub-
ble concentrations, prolate ellipsoid ablation lesions were
centered at the HIFU focal point. As microbubble concentra-
tions increased, larger ablation lesions became asymmetric
ellipsoids that migrated as much as 2 cm away from the focal
point toward the ultrasound source. Finally, at the highest
microbubble concentrations, the ablation lesions flattened
along the frontal phantom surface and “shadowed” deeper
sites such that no ablation occurred at the desired focal point.
The largest microbubble mediated ablation lesions were
achieved at a price of lost control over lesion geometry and
location both in Tung’s study and in this study.
FIG. 7. MR thermometry maps of phantoms containing no agents (top row),
ND (second to fourth rows) or MB (fifth and sixth rows). Frames shown
were collected during the 60 s of HIFU ablation and indicate the intensity
and location of the temperature change. The dotted line across each series of
frames delineates the surface of the phantoms.
FIG. 8. For each MR acquisition over time, the maximum change in temper-
ature (A) at the focus (ROI) and at the (B) surface of the phantom was
extracted from the corresponding horizontal slices from those locations.
Time curves were averaged, and data are presented as the means 6 s.d.
(n 3). Phantoms contained 0.01 ll of ND/MB per milliliter of phantom
material or no agents (control).
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Liquid nanodroplets offered advantages over microbub-
bles when exposed to HIFU in the tissue-mimicking model.
For a given concentration or pressure, lesions in response to
nanodroplets were significantly smaller than microbubble-
associated lesions. However, ablation lesions produced in the
presence of nanodroplets were less prone to shape change and
lesion migration than microbubble-enhanced lesions. MR ther-
mometry maps of phantoms containing nanodroplets revealed
HIFU heating in the phantom center and not at its surface. The
MR thermometry studies were performed at room temperature
because it was not straightforward to heat the phantoms to 37
inside the MR scanner. So it is possible that the nanodroplets
were not performing optimally. Vaporization is dependent
both on acoustic parameters and the ambient temperature.
Even greater thermal enhancement is therefore expected to
occur during HIFU ablation of nanodroplets at body tempera-
ture. Regardless, the results suggest that the energy required to
achieve phase transition of our novel liquid nanodroplet pro-
vides the opportunity to control the size and placement of abla-
tion lesions during PFC-enhanced HIFU.
Although we are working with nanodroplets, it is nota-
ble that the number of agents required to enhance ablation in
our studies is comparable to the number of microbubbles
injected during contrast imaging with Definity; this makes
the use of this technology more clinically feasible. In this
study, the presence of PFC nanodroplets in the tissue-
mimicking phantoms resulted in larger HIFU-induced abla-
tion lesions than could be achieved in control phantoms
without agent. Previous studies have also reported enhanced
HIFU ablation using liquid PFC droplets. Zhang et al.
(2011) demonstrated ablation lesions with volumes
approaching 600 mm3 in tissue-mimicking acrylamide phan-
toms containing an estimated concentration of 3 105
DDFP droplets/ml after 5 s of HIFU. Although these lesions
are notably larger than the ablation lesions reported in our
study, despite the shorter insonation time and the use of
pure, less-volatile DDFP, it should be noted that the droplets
were micron-sized and HIFU was applied at an intensity of
4000 W/cm2. The differences in the results highlight the fact
that the final ablation response during PFC-enhanced HIFU
depends on many factors, including PFC droplet characteris-
tics (boiling point, size, and concentration) as well as acous-
tic parameters (intensity and exposure duration).
Our studies demonstrate that by controlling vaporiza-
tion, the location of enhanced thermal energy deposition can
be controlled. Whereas microbubbles impede the acoustic
beam causing surface lesions and “shadowing” of the beam,
the nanodroplets do not impede the beam prior to vaporiza-
tion and allow for deeper lesion generation. We expect our
nanodroplets to be capable of extravasating due to their
100–300 nm diameters; however, this will be the focus of
future studies. Benefits of nanodroplet-enhanced HIFU
include shorter treatment times, decreased risk to healthy tis-
sue along the ultrasound path, and deeper access to tumors.
V. CONCLUSIONS
Our nanodroplet formulation offers several advantages
over microbubbles for HIFU ablation procedures.
Microbubble-enhanced HIFU ablation is complicated by sur-
face and non-targeted heating. In contrast, our nanodroplet
formulation does not substantially enhance thermal energy
deposition prior to vaporization. Because the nanodroplets
require sufficient energy for vaporization, targeted ablation
can be achieved at the focal point of the transducer inside
deep tissue. Nanodroplets were found to reduce the acoustic
energy and time required to ablate a tissue mimicking mate-
rial. As such, these nanodroplets have the potential both to
reduce the procedure time and to improve the safety of
focused ultrasound surgery.
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